Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Autor:	D.J. Vugts, Adrienne H. Brouwers, H. M. W. Verheul, M. C. Huisman, Wim J.G. Oyen, C. W.Menke van der Houven van Oordt, S. C. van Es, Sjoerd G. Elias, Otto S. Hoekstra, Sophie L. Gerritse, C.M.L. van Herpen, G.A.M.S. (Guus) van Dongen, Henk L. Dekker, E. J. van Helden, E.G.E. de Vries, Eline Boon, Ronald Boellaard, N.C.T. van Grieken
Rok vydání:	2020
Předmět:	Proto-Oncogene Proteins B-raf Oncology PET-CT medicine.medical_specialty Cetuximab business.industry Wild type Correction General Medicine Electronic Supplementary Material Proto-Oncogene Proteins p21(ras) Advanced colorectal cancer Positron Emission Tomography Computed Tomography Internal medicine Mutation medicine Humans Biomarker (medicine) Radiology Nuclear Medicine and imaging In patient Colorectal Neoplasms business Biomarkers medicine.drug
Zdroj:	Eur J Nucl Med Mol Imaging
ISSN:	1619-7089 1619-7070
Popis:	One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [PET/CT imaging of [Visual tumor uptake on [Tumor uptake on [
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf0153ac84553cb5c2f1f4820f039ff6 https://doi.org/10.1007/s00259-020-04908-6 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.